The cancer survival index-A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies.
prognosis
prognostic factor
psychosocial studies
survival
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
03
03
2022
received:
18
01
2022
accepted:
11
03
2022
pubmed:
23
3
2022
medline:
24
9
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
We aimed to investigate whether (1) psychological and social indicators influence survival in patients diagnosed with cancer or haematologic malignancies when important biological aspects are controlled for, (2) psychological, social and biological indicators can be utilised to design one collated index for survival, usable in clinical practice to identify patients at risk of shorter survival and to improve personalised healthcare provision. In this cross-sectional study, 2263 patients with cancer or haematologic malignancies participated. We analysed 15 biological, psychological and social indicators as risk factors for survival with a Cox proportional hazards model. Indicators significantly associated with survival were combined to compute models for the identification of patient groups with different risks of death. The training sample contained 1122 patients. Validation samples included the remaining 1141 patients, the total sample, as well as groups with different cancer entities. Five indicators were found to significantly impact survival: Cancer site (HR: 3.56), metastatic disease (HR: 1.88), symptoms of depression (HR: 1.34), female sex (HR: 0.73) and anaemia (HR: 0.48). Combining these indicators to a model, we developed the Cancer Survival Index, identifying three distinct groups of patients with estimated survival times of 47.2 months, 141 months and 198.2 months (p < 0.001). Post hoc analysis of the influence of depression on survival showed a mediating effect of the following four factors, related to both depression and survival: previous psychiatric conditions, employment status, metastatic disease and haemoglobin levels. Psychosocial and biological factors impact survival in various malignancies and can be utilised jointly to compute an index for estimating the survival of each patient individually-the Cancer Survival Index.
Identifiants
pubmed: 35315594
doi: 10.1002/cam4.4697
pmc: PMC9487871
doi:
Substances chimiques
Biological Factors
0
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3387-3396Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Nat Neurosci. 2009 Mar;12(3):342-8
pubmed: 19234457
J Clin Oncol. 2013 Feb 20;31(6):782-93
pubmed: 23319686
Psychooncology. 2019 Dec;28(12):2382-2388
pubmed: 31679172
Lancet. 2015 Mar 28;385(9974):1206-18
pubmed: 25479696
Cancer. 2001 Jun 15;91(12):2214-21
pubmed: 11413508
Cancer Med. 2022 Sep;11(18):3387-3396
pubmed: 35315594
PLoS Med. 2021 May 18;18(5):e1003595
pubmed: 34003832
J Geriatr Oncol. 2021 May;12(4):612-617
pubmed: 33158770
J Natl Cancer Inst. 2009 Nov 4;101(21):1464-88
pubmed: 19826136
J Clin Oncol. 2009 Jun 20;27(18):3044-51
pubmed: 19451447
Cancer Causes Control. 2010 Feb;21(2):191-9
pubmed: 19885645
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372
Cancer Causes Control. 2009 May;20(4):417-35
pubmed: 19002764
N Engl J Med. 2012 Mar 8;366(10):956-7
pubmed: 22397658
Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1717-1725
pubmed: 34244160
Lancet. 1999 Oct 16;354(9187):1331-6
pubmed: 10533861
Psychiatry Res. 2011 May 15;187(1-2):106-12
pubmed: 21126772
Lancet Oncol. 2011 Sep;12(10):928-9
pubmed: 21958500
Nat Clin Pract Oncol. 2008 Aug;5(8):466-75
pubmed: 18493231
J Clin Oncol. 2012 Apr 10;30(11):1227-34
pubmed: 22412124
J Clin Oncol. 2008 Dec 20;26(36):5863-9
pubmed: 19018082
Int J Cancer. 2007 Dec 1;121(11):2524-31
pubmed: 17680561
Eur J Cancer. 2011 Apr;47(6):910-7
pubmed: 21145729
Br J Cancer. 2012 Feb 28;106(5):988-95
pubmed: 22315055
J Clin Oncol. 2008 Oct 1;26(28):4666-71
pubmed: 18824713
J Clin Oncol. 2010 Sep 10;28(26):4086-93
pubmed: 20644100
Int J Cancer. 2022 Jul 1;151(1):77-82
pubmed: 35128650
Psychooncology. 2021 Apr;30(4):504-510
pubmed: 33210393
J Clin Oncol. 2010 Jan 20;28(3):380-6
pubmed: 20008637
Cancer. 2009 Nov 15;115(22):5349-61
pubmed: 19753617
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Clin Oncol. 2012 Apr 10;30(11):1215-20
pubmed: 22412133
Mol Psychiatry. 2020 Jul;25(7):1487-1499
pubmed: 31745237
J Clin Oncol. 2011 Feb 1;29(4):413-20
pubmed: 21149651
J Clin Oncol. 2004 Oct 15;22(20):4184-92
pubmed: 15483029
Breast Cancer Res Treat. 1992;22(3):207-19
pubmed: 1391987
BJS Open. 2020 Feb;4(1):133-144
pubmed: 32011820
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):45-52
pubmed: 33082205
J Psychosom Res. 2007 Jul;63(1):83-91
pubmed: 17586341
J Clin Oncol. 2013 Jul 20;31(21):2724-9
pubmed: 23775970
J Clin Oncol. 2008 Sep 1;26(25):4116-23
pubmed: 18757325
J Clin Oncol. 2011 Oct 10;29(29):3885-91
pubmed: 21900114
J Clin Oncol. 2011 Feb 1;29(4):406-12
pubmed: 21172892
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
J Clin Oncol. 2006 Nov 10;24(32):5132-7
pubmed: 17093275
J Natl Cancer Inst. 2011 May 4;103(9):714-36
pubmed: 21454908
PLoS One. 2012;7(7):e39013
pubmed: 22848347
Womens Health Rep (New Rochelle). 2021 Oct 04;2(1):464-472
pubmed: 34841392